普拉克索联合左旋多巴治疗帕金森病的临床疗效及安全性  

Clinical efficacy and safety of levodopa combined with pramipexole in treatment of Parkinson'S Disease

作　　者：周永[1] 陈蓝[1] 戴杰 顾承志[1] 李嘉[1] 朱连海[1] 黄国祥[1] ZHOU Yong;CHEN Lan;DAI Jie;GU Chengzhi;LI Jia;ZHU Lianhai;HUANG Guoxiang(Nantong First People's Hospital,Intemal Medicine-Neurology,Nantong 22600,China)

机构地区：[1]南通市第一人民医院神经内科,江苏南通226001

出　　处：《药物评价研究》2018年第12期2262-2265,共4页Drug Evaluation Research

基　　金：2015年度南通市民生示范推广项目(MS32015033)

摘　　要：目的探讨左旋多巴联合普拉克索治疗帕金森病的临床疗效及安全性。方法选取2015年8月—2017年12月于南通市第一人民医院神经内科门诊或住院诊治的帕金森病患者150例,采用随机法分为观察组(80例)和对照组(70例),对照组患者仅给予左旋多巴进行治疗,观察组患者给予左旋多巴联合普拉克索进行治疗,持续服药12周,比较两组患者帕金森病综合评估量表(UPDRS)II和UPDRS III、汉密顿抑郁量表(HAMD)及不良反应的发生率。结果治疗前,两组患者的UPDRS II和UPDRS III评分相比,差异无统计学意义;经治疗后,两组患者UPDRS II和UPDRS III评分均显著降低,同组治疗前后比较差异有统计学意义(P<0.05);与对照组相比,观察组患者UPDRS II和UPDRS III评分显著低于对照组,差异有统计学意义(P<0.05)。治疗后,两组患者的HAMD评分显著降低,同组治疗前后比较差异有统计学意义(P<0.05);与对照组治疗后相比,观察组患者的HAMD评分显著降低,差异具有统计学意义(P<0.05)。观察组患者不良反应发生率为13例(16.25%),对照组患者不良反应发生率为9例(12.86%),差异无统计学意义。结论左旋多巴联合普拉克索治疗帕金森病的临床疗效较好,且安全可靠。Objective To investigate the clinical efficacy and safety of levodopa combined with pramipexole in the treatment of Parkinson's Disease.Methods 150 cases Parkinson's Disease patients from August 2015 to December 2017 in the First People's Hospital of Nantong were randomly divided into treatment group(80 cases)and control group(70 cases),the treatment group was given levodopa combined with pramipexole,the control group was given levodopa,compared with the unified Parkinson's Disease rating scale Ⅱ,unified Parkinson's Disease rating scale Ⅲ,hamilton depression scale and incidence of adverse reaction.Results Before treatment,compared with the UPDRS Ⅱ,UPDRS Ⅲ and HAMD score of the two group,the difference was not statistically significant.After treatment,compared with the control group,the UPDRS Ⅱ,UPDRS Ⅲ and HAMD score significantly decreased of the treatment group,with significant difference(P<0.05).The incidence of adverse reaction of the treatment group is 13 cases(16.25%),the incidence of adverse reaction of the control group is 9 case(12.86%),compared with the two groups,the difference was not statistically significant.Conclusion Levodopa combined with pramipexole has good effect in the treatment of Parkinson's Disease,and the safety is high.

关 键 词：左旋多巴 普拉克索 帕金森病 疗效 安全性 

分 类 号：R969[医药卫生—药理学]